ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Erdafitinib-releasing Intravesical System TAR-210

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms, led by Johnson & Johnson.

Furthest: phase 3, since Mar 13, 20242 company-led studies, 2 open or runningNext primary completion: Apr 6, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson22 open or runningphase 3since Mar 13, 2024Mar 13, 2024Apr 6, 2028phase 3 · NCT06919965

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2024First study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsFirst studyNCT06319820 · 641 planned · United States, Argentina, Austria and more
  2. Apr 2, 2025Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT06919965 · 220 planned · United States, Argentina, Belgium and more

Ahead

  1. Apr 6, 2028Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT06919965
  2. Jun 28, 2028Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT06319820

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06919965Non-Muscle Invasive Bladder Neoplasms · United States, Argentina, Belgium and more3RecruitingApr 6, 2028220
NCT06319820Non-Muscle Invasive Bladder Neoplasms · United States, Argentina, Austria and more3RecruitingJun 28, 2028641

How it is read

Names in the registry

  • “TAR-210”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.